Lung cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• EGFR 301
• PD-L1 162
• PD-1 157
• KRAS 98
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• mTOR 0
• VEGF 23
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• RAS 15
• CTNNB1 0
• TROP2 13
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

EU-13 is a filter, not a ranking: it only narrows the list.

17 of 17+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Merus B.V.· Updated 26 Oct 2026

  “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”Registry text, quoted unchanged. Source

• Terminated

  Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

  NCT04982224· Regeneron Pharmaceuticals· Updated 3 Nov 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

  NCT04926831· Novartis Pharmaceuticals· Updated 16 Oct 2025

  “The study was terminated early due to recruitment challenges.”Registry text, quoted unchanged. Source

• Withdrawn

  Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

  NCT06093503· AbbVie· Updated 26 Jun 2024

  “Strategic considerations”Registry text, quoted unchanged. Source

• Withdrawn

  Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

  NCT05567055· Timothy Burns, MD, PHD· Updated 17 Jun 2024

  “Slow enrollment”Registry text, quoted unchanged. Source

• Terminated

  Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

  NCT05435846· Collin Blakely· Updated 11 Jun 2024

  “slow accrual”Registry text, quoted unchanged. Source

• Withdrawn

  A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

  NCT04460729· Novartis Pharmaceuticals· Updated 3 Dec 2020

  “company decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Premedication to Reduce Amivantamab Associated Infusion Related Reactions

  NCT05663866· Janssen Research & Development, LLC· Source

• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  NCT04928846· AbbVie· Source

• A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)

  NCT07613424· AstraZeneca· Source

• Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

  NCT05110196· Novartis Pharmaceuticals· Source

• A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  NCT06568939· AbbVie· Source

• Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors

  NCT07863024· Regeneron Pharmaceuticals· Source

• A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT07821684· AbbVie· Source

• A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

  NCT06147037· AstraZeneca· Source

• A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

  NCT04077099· Regeneron Pharmaceuticals· Source

• Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

  NCT03040973· Novartis Pharmaceuticals· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 314
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 67
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 191
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 616
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 115
• Machine Learning 290
• Deep Learning 210
• Cohort Studies 289
• Genome-Wide Association Study 75

• Causal effects of educational attainment on respiratory diseases: A Mendelian randomization study.

  Medicine (Baltimore), Oct 2026

• PLCG1 regulates pyroptosis to inhibit the progression of non-small cell lung cancer: A Mendelian randomization study.

  Medicine (Baltimore), Oct 2026

• Causal relationship between oral microbiome, circulating inflammatory proteins and lung cancer: A Mendelian randomization study.

  Medicine (Baltimore), Oct 2026

• Contributions of smoking behaviour to lung cancer subtypes: A two-sample Mendelian randomization study.

  Medicine (Baltimore), Oct 2026

• Genetic evidence for associations between gastroesophageal reflux disease and site-specific extraesophageal cancers: A Mendelian randomization study.

  Medicine (Baltimore), Oct 2026

• Lung cancer and altered brain structure: A causal inference based on MR.

  Medicine (Baltimore), Sept 2026

• Unveiling the association between plasma lipid species and pan-cancers: A bidirectional 2-sample Mendelian randomization study.

  Medicine (Baltimore), Sept 2026

• Causal association between clonal hematopoiesis indeterminate potential and cancer: a Mendelian randomization study.

  Exp Biol Med (Maywood), Jul 2026

• Assessing the causal effects of environmental tobacco smoke exposure: a meta-analytic Mendelian randomization study.

  Nicotine Tob Res, Jul 2026

• Genetic evidence for a potential role of cytoskeleton-associated protein 2 in lung squamous cell carcinoma: a bidirectional mendelian randomization study.

  J Cardiothorac Surg, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.